Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 May 31;11:74. doi: 10.1186/s13045-018-0557-9

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s). 2018

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Fig. 4 — Pathologically, EGFR and SAE2 were concurrently expressed in LADC patients with poor survival. a Using a Western blotting method, expression of EGFR was detected with various molecular weights in 18 tumor and eight non-tumor fractions of 20 pair of LADC biopsies. β-actin was used as a monitoring standard. b Using the same method, expression of SAE2 was detected as a 100-kDa protein in 19 tumor and two non-tumor fractions of LADC specimens. N non-tumor lung tissue (NTLT), T tumor fraction of surgical resections. c Representative examples of SAE2 expression in pathological specimens of LADC was determined by immunohistochemical staining (crimson precipitates). Expression of SAE2 was detected in the LADC tumor nests of (c1) papillary, (c2) acinar, (c3) solid, and (c4) mixed subtypes. (c5) In the NTLT, signal of SAE2 was detected in type II pneumocytes (the enlarged area), but not in type I pneumocytes of the air sac. d Comparison of Kaplan-Meier product limit estimates of survival analysis in LADC patients. (d1) Patients were divided into two groups depending on the expression of SAE2. The difference in survival between the two groups was compared by the log-rank test. Survival of patients with low SAE2 level was significantly better than those with high SAE2 level. The hazard ratio between these two groups was 1.708, and the difference in cumulative survival was significant (P = 0.002). (d2) Survival of stage I patients with low SAE2 level was significantly better as well. The hazard ratio was 4.08, and the difference in cumulative survival was significant (P = 0.0053)